Abstract
On page 1173 in Table 3, “Abnormal cervical lymph nodes” and “Microcalcifications present in nodule” should have been presented as main entries under the heading “Nodule sonographic or clinical features,” but were erroneously indented as subentries of “High-risk history.” On page 1181 in Table 4, the citation of the AJCC Staging Manual (2) was inadvertently omitted from the References section. On page 1187 in Figure 4, the thyroglobulin levels used in the algorithm that follows the branching downward arrow after “US Negative” should be “Tg >1,b Tg Ab Neg” in the left box and “Tg <1, Tg Ab Pos” in the right box. In each of these boxes 0.3 was mistakenly presented instead of 1. On page 1187 in the legend to Figure 4, two citations were inadvertently omitted from the References section: Preissner et al., 2005 (3); and Preissner et al., 2003 (4). On page 1187 in the legend to Figure 4, the citations of Chiovato et al., 2003 (5), and Spencer et al., 1998 (6), should have been listed as references “306” and “305”, respectively.
High-risk history: History of thyroid cancer in one or more first degree relatives; history of external beam radiation as a child; exposure to ionizing radiation in childhood or adolescence; prior hemithyroidectomy with discovery of thyroid cancer, 18FDG avidity on PET scanning; MEN2/FMTC-associated RET protooncogene mutation, calcitonin >100 pg/mL. MEN, multiple endocrine neoplasia; FMTC, familial medullary thyroid cancer.
Suspicious features: microcalcifications; hypoechoic; increased nodular vascularity; infiltrative margins; taller than wide on transverse view.
FNA cytology may be obtained from the abnormal lymph node in lieu of the thyroid nodule.
Sonographic monitoring without biopsy may be an acceptable alternative (see text) (48).
Unless indicated as therapeutic modality (see text).
Longer term follow-up of patients with differentiated thyroid carcinoma.
The authors sincerely apologize for these errors.